Having trouble accessing articles? Reset your cache.

Making vaccines is no yolk

Conventional production of influenza vaccine in eggs has multiple limitations, which has spurred work on cell-based approaches. iBio Inc.and theFraunhofer USA Center for Molecular Biotechnologyhave been working on a third approach-plant-based vaccine production-and in September took an H1N1 influenza vaccine generated using their process into a Phase I trial.

The partners believe the platform could generate vaccine more cheaply and rapidly than the traditional egg-based method of flu vaccine production while requiring less investment in manufacturing infrastructure than cell culture approaches.

Influenza vaccine production still relies on a 50-year-old method that involves growing the flu virus in hens' eggs, breaking the eggs open

Read the full 1010 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers